The effects of repeated low-dose sarin exposure

Shih, T-M., Hulet, SW, McDonough, JH

US Army Medical Research Institute of Chemical Defense
ATTN: MCMR-CD-P
3100 Ricketts Point Road

Approved for public release; distribution unlimited


Organophosphate, nerve agent, sarin, cholinesterase inhibitors, repeated exposure, acetylcholinesterase, functional observation battery, body weight, seizures, electroencephalogram, acetylcholine, choline, in vivo microdialysis, pathology

SECURITY CLASSIFICATION OF:

b. ABSTRACT
UNCLASSIFIED

16. LIMITATION OF ABSTRACT
UNLIMITED

17. NUMBER OF PAGES
16

19a. NAME OF RESPONSIBLE PERSON
Tsung-Ming Shih

19b. TELEPHONE NUMBER (include area code)
410-436-3414

Standard Form 298 (Rev. 8-98)
Prescribed by ANSI Std. Z39.18
The effects of repeated low-dose sarin exposure

T.-M. Shih, S.W. Hulet, J.H. McDonough

Pharmacology Branch, Research Division, U.S. Army Medical Research Institute of Chemical Defense, 3100 Ricketts Point Road, Aberdeen Proving Ground, MD 21010-5400, USA

Received 10 December 2005; revised 6 February 2006; accepted 10 February 2006

Abstract

This project assessed the effects of repeated low-dose exposure of guinea pigs to the organophosphorus nerve agent sarin. Animals were injected once a day, 5 days per week (Monday–Friday), for 2 weeks with fractions (0.3 ×, 0.4 ×, 0.5 ×, or 0.6 ×) of the established LD50 dose of sarin (42 µg/kg, s.c.). The animals were assessed for changes in body weight, red blood cell (RBC) acetylcholinesterase (AChE) levels, neurobehavioral reactions to a functional observational battery (FOB), cortical electroencephalographic (EEG) power spectrum, and intrinsic acetylcholine (ACh) neurotransmitter (NT) regulation over the 2 weeks of sarin exposure and for up to 12 days postinjection. No guinea pig receiving 0.3, 0.4 or 0.5 × LD50 of sarin showed signs of cortical EEG seizures despite decreases in RBC AChE levels to as low as 10% of baseline, while seizures were evident in animals receiving 0.6 × LD50 of sarin as early as the second day; subsequent injections led to incapacitation and death. Animals receiving 0.5 × LD50 sarin showed obvious signs of cholinergic toxicity; overall, 2 of 13 animals receiving 0.5 × LD50 sarin died before all 10 injections were given, and there was a significant increase in the angle of gait in the animals that lived. By the 10th day of injection, the animals receiving saline were significantly easier to remove from their cages and handle and significantly less responsive to an approaching pencil and touch on the rump in comparison with the first day of testing. In contrast, the animals receiving 0.4 × LD50 sarin failed to show any significant reductions in their responses to an approaching pencil and a touch on the rump as compared with the first day. The 0.5 × LD50 sarin animals also failed to show any significant changes to the approach and touch responses and did not adjust to handling or removal from the cage from the first day of injections to the last day of handling. Thus, the guinea pigs receiving the 0.4 and 0.5 × LD50 doses of sarin failed to habituate to some aspects of neurobehavioral testing. Spectral analysis of EEG data suggested that repeated sarin exposure may disrupt normal sleeping patterns (i.e., lower frequency bandwidths). While these EEG changes returned to relative normalcy 6 days after the last injection in animals receiving 0.4 × LD50 sarin, these changes were still observed in the animals that received 0.5 × LD50 sarin. Ten to twelve days after the last sarin injection (in 0.4 × LD50 group only), neurochemical data showed that striatal choline levels were reduced in comparison to the saline group. At this time, atropine sulfate (5 mg/kg, i.p.) challenge resulted in a transient elevation in striatal ACh levels in animals exposed to repeated 0.4 × LD50 sarin as well as in control animals. No evidence of brain or heart pathology was found in any guinea pig that survived all 10 sarin injections.

Published by Elsevier Inc.

Keywords: Organophosphorus; Nerve agent; Sarin; Cholinesterase inhibitors; Repeated exposure; Acetylcholinesterase; Functional observational battery; Body weight; Seizures; Electroencephalogram; Acetylcholine; Choline; In vivo microdialysis; Pathology

Abbreviations: ACh, acetylcholine; AChE, acetylcholinesterase; CWNA, chemical warfare nerve agent; DFP, diisopropylfluorophosphate; DOPAC, 3,4-dihydroxyphenylacetic acid; EEG, electroencephalographic activity; FOB, functional observational battery; HPLC, high pressure liquid chromatograph; HVA, homovanillic acid; i.m., intramuscular; i.p., intraperitoneal; LC50, median lethal concentration; LD50, median lethal dose; MTD, maximum tolerated dose; NT, neurotransmitter; OP, organophosphorus compound; RBC, red blood cell; s.c., subcutaneous.

© 2006 Published by Elsevier Inc.

E-mail address: tsangming.a.shih@us.army.mil (T.-M. Shih).

Corresponding author. Fax: +1 410 436 2072.

Current address: Research and Technology Directorate, US Army Edgewood Chemical and Biological Center, Aberdeen Proving Ground, MD 21010, USA.

doi:10.1016/j.taap.2006.02.003
Introduction

Chemical warfare nerve agents (CWNAs), such as sarin, soman, and VX, are organophosphorus compounds (OPs). They disrupt normal nervous system transmissions through the irreversible inhibition of acetylcholinesterase (AChE), the enzyme that breaks down the cholinergic neurotransmitter (NT) acetylcholine (ACh). The buildup of ACh in response to a large exposure to nerve agents can lead, unless promptly treated, to muscle weakness, increased secretions (i.e., lacrimation, rhinorrhea, salivation), convulsions and seizures, respiratory depression, coma, and death (Taylor, 2001). The progression of signs, their neuropathological basis, and toxic consequence elicited from acute high-dose exposures have been well characterized (McDonough and Shih, 1993, 1997; Shih et al., 2003). However, much less is known about the long-term effects of repeated low-dose CWNA exposure. Comprehensive reviews of the available literature on the long-term health effects of exposure to low level CWNAs have been published (Panel on Anticholinesterase Chemicals, 1982; Coordinating Subcommittee, 1985; Moore, 1998; Romano et al., 2001). In general, exposure to low-level CWNAs is a potential emerging health hazard that requires further investigation (Romano et al., 2001).

In the great majority of the available literature on repeated low-dose exposure to CWNAs, soman is the OP studied most often. Repeated low-dose soman exposure has been investigated in mice (Sterri et al., 1980), rats (Sterri et al., 1980; Dulaney et al., 1985; Hymowitz et al., 1985; Kerenyi et al., 1990; Shih et al., 1990; Howerton et al., 1991), guinea pigs (Sterri et al., 1981, 1982), and primates (Gause et al., 1985; Blick et al., 1991, 1994). The effects of the repeated soman exposures, cited above, ranged from performance decrements on a well-learned compensatory tracking task (Blick et al., 1994) to development of attention deficits (Gause et al., 1985) to hyper-reactive responses to handling (Shih et al., 1990).

Unlike soman, the nerve agent sarin has been used previously by extreme terrorist groups (e.g., 1995 Tokyo subway incidence; Nozaki et al., 1995) and on the battlefield (MaciIwain, 1993; Brown and Brix, 1998). More than 98,000 Persian Gulf War veterans have been notified that they were potentially exposed to a plume of sarin when American forces destroyed an ammunition depot shortly after the end of the 1991 Gulf War (Enserrink, 2001). The amount of literature regarding the effects of repeated low-level exposure to sarin is rather sparse and, at times, conflicting. Burchfiel et al. (1976) exposed rhesus monkeys to repeated low levels of sarin (1 μg/kg, i.m.) once per week for 10 weeks. Despite increases in high frequency beta activity upon electroencephalographic (EEG) analysis, there were no signs of adverse health or long-term behavioral effects. In contrast, when sarin was administered subcutaneously (s.c.) to rats once per day for up to 85 days, doses less than 0.3 × LD_{50} resulted in significant reductions in body weight gains by as early as the 7th day of injections while a dose of approximately 0.36 × LD_{50} resulted in the death of 4 out of 11 animals by the 10th day of injections (Dulaney et al., 1985). Husain et al. (1993), using a repeated inhalation protocol (5 mg/min/m^3 for 20 min per day for 10 days) in mice, reported that sarin exposure amounting to less than 0.2 × LC_{50}/day resulted in delayed (14th day after exposure) muscle twitching, weakness in the extremities, and slight ataxia. It has been observed in rats and mice that intraperitoneal (i.p.) injections of subtoxic doses of sarin or soman decreased locomotor activity, altered behavior on the plus-maze, and elevated horizontal bridge tests (Sirkka et al., 1990; Nieminen et al., 1990; Baille et al., 2001). Kassa et al. (2001a, 2001b) concluded that repeated low-level sarin inhalation in rats at clinically asymptomatic doses was disruptive to neurophysiological function and caused long-term memory impairments. Whereas, Conn et al. (2002) reported that low-level sarin inhalation exposure did not change body temperature and locomotor activity during exposure or for 1 month postexposure.

It was hypothesized by Metcalf and Holmes (1969) that exposure to OPs can induce irreversible or slowly reversible brain dysfunction. Indeed, this theory has been supported by studies investigating EEG changes in response to high dose or repeated, low-level, asymptomatic OP exposures in both non-human primates (Burchfiel et al., 1976) and humans (Metcalf and Holmes, 1969; Duffy et al., 1979; Wadia et al., 1974).

Changes in both extracellular NT levels measured by in vivo microdialysis techniques and total NT levels measured in brain homogenates, following exposure to high (e.g., near lethal) doses of CWNAs, have been documented in animal studies. Upon exposure to CWNAs, increases in brain ACh levels occur rapidly, but return to baseline levels extracellularly within 90 min of seizure onset (Shih, 1982; Shih and McDonough, 1997; Shih et al., 1993; Fosbraey et al., 1990, 1991; Lallement et al., 1992). Increases in extracellular glutamate levels as well as dopamine metabolites, i.e., 3,4-dihydroxyphenylacetic (DOPAC) and homovanillic acid (HVA), are also evident in brain following onset of CWNA-induced seizure activity (Lallement et al., 1991; Shih and McDonough, 1997; McDonough and Shih, 1997). Whether there are changes in brain NT levels upon repeated low-dose exposure to CWNA is less clear. Although it has already been shown that chronic exposure to nerve agent may result in down-regulation of cholinergic receptors (Churchill et al., 1984), the effects that chronic elevation of extracellular NTs, such as ACh and glutamate, might have on receptor numbers or on responses to agonists have yet to be defined.

The objective of the current study was to expand on a previously reported model for repeated sarin exposure in the guinea pig that did not elicit severe signs of OP intoxication when injected once per day (Monday–Friday) over a 2-week period (Atchison et al., 2004). We hypothesized that the long-term abnormalities associated with repeated exposure to low-dose OPs, previously identified in EEG spectra (Burchfiel et al., 1976), are most likely linked with alterations in normal neuropharmacological homeostasis. Therefore, we investigated...
what effect this dosing regimen has on EEG power spectra and determined whether the animals exhibit predictable neurochemical changes in response to drugs that result in changes in the intrinsic NT regulation. In addition, we assessed whether subtle neurobehavioral and/or physical deficits developed as a result of the 2 weeks of sarin exposures. As a positive control, a dose group that did.

Materials and methods

Animals

Male Hartley guinea pigs (Crt(HA)BR; Charles River Labs, Kingston, NY; 290–430 g starting weight) were used for these studies. They were individually housed in polyurethane cages in temperature (21 ± 2 °C) and humidity (50 ± 10%) controlled animal quarters maintained on a 12-h light-dark full spectrum lighting cycle with lights on at 0600 h. Laboratory chow and water were freely available whenever the animals were in home cages. The research environment and protocols for animal experimentation were approved by the institutional animal care and use committee. The animal care program at this Institute is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International.

Surgery

Guinea pigs were anesthetized with isoflurane and surgically implanted with cortical screw electrodes using standard small animal aseptic surgical techniques (Shih and McDonough, 1999). Small burr holes were drilled in the skull to accept stainless steel screw electrodes (equidistance between bregma and lambda and 3 mm lateral to the midline suture) and an intracerebral guide cannula (BAS #MD-2220) for a microdialysis probe. The tip of the guide cannula was lowered into the coordinates (AP = +11.4; L = +3.6; Depth = −4.6) for caudate nucleus (Lupparelli, 1968). The electrode leads were connected to a miniature connector plug. The wires, screws, plug, and guide cannula were held in place using cranioplast cement. The guinea pigs were administered buprenorphine (0.03 mg/kg, s.c.) for pain management immediately following surgery and allowed to recover for 10–14 days before experiments began.

Materials

Sarin was obtained from the US Army Edgewood Chemical Biological Center (Aberdeen Proving Ground, MD). It was diluted in saline in concentrations to deliver injection volumes = 0.5 ml/kg, and the diluted solution was maintained on ice prior to administration. The Institute’s historic database indicated that the LD₅₀ for sarin in the guinea pig to be 42 μg/kg (s.c.); subsequent dosing was based on this value. Atropine sulfate (Sigma-Aldrich Co., St. Louis, MO) was diluted in saline (0.5 ml/kg) before administration. Pentobarbital (Nembutal) was purchased from Abbott Laboratories (Chicago, IL). Isoflurane (Attane, USP) was obtained from Minrad, Inc. (Bethlehem, PA). Orthophosphoric acid (55%, HPLC grade), disodium ethylenediamine tetraacetate (EDTA), and 10% neutral buffered formalin were purchased from Fisher Scientific (Pittsburgh, PA). Neostrigine bromide, acetycholine chloride, and choline chloride were purchased from Sigma-Aldrich Co. All other chemicals used were analytical reagent grades.

Experimental protocol

Guinea pigs were administered selected doses of sarin or saline (as control) once per day, 5 days per week (Monday–Friday) for 2 weeks. The injections were administered s.c. under the skin of the back in a volume of 0.5 ml/kg body weight. The s.c. route of administration was chosen based on the fact that there is minimal first-pass detoxification of the agent by the liver by this route (Dulaney et al., 1985; Shih et al., 1990; Sterri et al., 1989, 1981, 1982). A pilot study was first performed to determine what dose of sarin could be repeatedly injected over the 2-week period that did not elicit signs of nerve agent intoxication. The doses of sarin tested in this pilot study were 0.3, 0.4, 0.5, and 0.6 × LD₅₀ (n = 4 animals at each dose). Baseline EEG recordings were taken for 10 min prior to all sarin injections, and EEG recordings were continued for an additional 40 min following sarin injections. In the pilot study, the guinea pigs were monitored for epileptiform EEG activity, changes in body weight, and red blood cell (RBC) AChE levels. From the results obtained in the pilot study, the 0.4 × LD₅₀ and 0.5 × LD₅₀ doses of sarin were chosen as the doses to be injected in the full experiment, along with saline for the controls. In the full study, guinea pigs were randomly assigned to treatment groups (saline, 0.4 × LD₅₀ or 0.5 × LD₅₀ sarin). The experiment was run in a series of replications, with each replication consisting of 8–10 guinea pigs randomly distributed between the 3 treatment conditions. In the full experiment, the same regimen of sarin dosing and monitoring of EEG, body weight, and RBC AChE was used. In addition, the animals were evaluated with a functional observational battery (FOB) to determine neurobehavioral function. FOB evaluation was performed on the animals prior to the 1st sarin or saline injection (baseline) and then after the sarin or saline injections on the 3rd, 5th, 6th, 8th, and 10th days. It was also performed on the 4th and 6th days following termination (recovery period) of injections. FOB was performed immediately after the EEG evaluation, 40–50 min after injections on exposure days. Blood was drawn for RBC AChE determinations prior to the 1st and 6th (following weekend recovery) sarin or saline injections and 2–3 h after the 2nd, 5th, 7th, and 10th injections. The animals were allowed to recover for 21 days after the last injection with RBC AChE measurements taken on the 4th, 7th, 14th, and 21st days of recovery. To minimize animal discomfort, the blood draws were staggered such that blood was not drawn from every animal on every day of blood collection.

AChE assay

Approximately 0.5 ml of blood was collected via toe-nail clip (Vallejo-Freire, 1951). This sample was prevented from clotting by the addition of 15 μl EDTA (4 g/l) and separated into plasma and RBC by centrifugation (11 min, 14,000xg). RBC AChE activity was determined, using acetylthiocholine iodide as a substrate, by an automated Ellman et al. (1961) method modified for a COBAS/FARA clinical chemistry analyzer (Roche Diagnostics Inc., Nutley, NJ) by Hobson et al. (1988).

Neurobehavioral (FOB) testing

The FOB is a sequence of rapid tests used to assess neurological functions (Bowen and Balster, 1997; Moser et al., 1988; Tegeris and Balster, 1994; Youssef and Santi, 1997). Two technicians, who were unaware of the treatment of the animals, performed all FOB scoring. The order of animal selection for the neurobehavioral testing was performed randomly by the scorer. The scoring sheet (see Appendix A) was adapted from those previously published (Moser et al., 1988; Youssef and Santi, 1997), with slight modifications for guinea pigs. The specific sequence of testing was as follows.

Home cage. While in the home cage, the guinea pigs were scored positive or negative for the presence of agitation, chewing, tremors, facial dysmorphism, and vocalizations. They were graded for ease of removal, ease of handling and presentation of physical signs, such as fur appearance (piloerection), emaciation, lacrimation, and salivation.

Open field. The animals were placed on top of a lab cart and latency to first movement was timed. The animals were then allowed to move freely for 2 min. During this time, the animals were scored on their gait description and their level of arousal. The number of grooms, urine spots, fecal matter, and rears was counted and recorded.

Reflexes. The guinea pig’s responses to an approaching pencil, a tap on the rear, and a loud click behind the head were graded. Righting reflex was then
measured by placing the animal on its back and recording the time it took for the guinea pig to get to its feet. For the drop reflex, the guinea pig was then dropped, from a supine position, from a height of 30 cm onto a soft landing area. The ease of the landing was scored.

Splay and gait. The guinea pig’s hindlimbs were painted with water-based tempura paint. Hindlimb foot splay was obtained by dropping the guinea pig, from a prone position, from approximately 30 cm high onto a sheet of paper placed on the countertop. The distance between the middle toes of each footpad was measured. The footpads were then repainted and the guinea pigs were placed on a new sheet of paper and allowed to walk freely. The testing was concluded when the guinea pigs maintained forward movement for a minimum of 3 successive steps in a straight path. The angle from the first footstep to the second and third steps was measured.

EEG recording and power spectral analysis

Instrumented animals were placed in individual chambers (45 cm H × 30 cm W × 25 cm D) and connected to the EEG recording apparatus. EEG recordings were made using amplifiers and software supplied by Neurodata INC. (Pasadena, CA) (low frequency filter = 0.3 Hz; high frequency filter = 40 Hz; sampling rate = 128 Hz) and displayed on a computer monitor. Baseline EEG recordings were taken for 10 min prior to all sarin injections, and continued for an additional 40 min following sarin injections. After sarin injections were terminated (recovery period), EEGs were recorded on day 6 of recovery. Development of epileptic seizure activity was operationally defined as the appearance of ≥10 s of rhythmic high amplitude spikes or sharp wave activity in the EEG.

For power spectral analysis, each recording session of 50 min was divided into 7 time periods as follows: BL = the baseline period before injections; IN = 0–6 min following injection; P1 = 6–12 min following injection; P2 = 12–18 min following injection; P3 = 18–24 min following injection; P4 = 24–30 min following injection; and P5 = 30–36 min following injection. Within each time period, a contiguous 120-second time snippet was taken for analysis. Each 120-s time snippet was taken as close to the beginning of the time period as possible (with the exception being the BL time period where the snippet was taken in the 120 s just prior to the injection being given). The total EEG cortical power consisted of bandwidth powers over 5 different frequency ranges as follows: Delta = 1–3.5 Hz; Theta = 4–7.5 Hz; Alpha = 8–12.5 Hz; Beta I = 13–20.5 Hz; and Beta II = 21–31.5 Hz. Analysis was done on total EEG power as well as on the 5 different frequency bandwidth powers. The means of spectral powers for a particular day, time point, and treatment were calculated.

In vivo microdialysis

Ten to twelve days following the last sarin or saline injection, a brain microdialysis probe (BR-2 probe, 2 mm membrane, BAS #MD-2200) was inserted into the intracerebral guide cannula. Baseline microdialysis samples were collected (15 min per fraction) from the conscious freely moving guinea pigs for a minimum of 1.5 h, while infusing the caudate nucleus with saline containing 2 μM neostigmine at 3 μl/min. The animals were then injected (i.p.) with 5 mg/kg of atropine sulfate. Microdialysis samples were collected for an additional 2 h and analyzed for ACh and choline levels.

Determination of ACh and choline

A BAS200 high-pressure liquid chromatograph (HPLC) with electrochemical detector (Bioanalytical Systems, Inc. (BAS), West Lafayette, IN) was used for determination of ACh and choline in the microdialysates (Huang et al., 1995). Twenty microliters of the collected microdialysis perfusate were injected directly into the HPLC at a flow rate of 0.05–0.1 ml/min in an isocratic mobile phase that consisted of 14.65 M phosphoric acid (pH 8.5) and 5 ml/l Kathon CG reagent (BAS #CF-2150) in deionized water. An ACh microbore column (1 × 530 mm ID, 10 μm UniJet, BAS #MF-8904) coupled with AChE/choline oxidase immobilized enzyme reactor (BAS #MF-8903) was used to separate ACh and choline. A “biosensor” was created by coating a glassy carbon electrode with a redox polymer film containing horseradish peroxidase (BAS Peroxidase Electrode Kit, Item No. MF-2095) and operated at +100 mV vs. Ag/AgCl. The redox polymer electrically “wires” the peroxidase to the electrode for the reduction of hydrogen peroxide that was generated from the immobilized enzyme reactor. The detector was set at [1]0.0 and [1]50.0 nanomols for optimum ACh and choline detection, respectively. The cell temperature was set at 35°C and the back pressure of this system was at 2000 PSI under optimal conditions. Retention times were approximately 10 min for ACh and 12 min for choline. Samples were quantified using BAS Report Software.

Pathology evaluation

Within 1 month of the animals’ last sarin or saline injection, the guinea pigs were deeply anesthetized with pentobarbital (75 mg/kg, i.p.) and then perfused through the aorta with saline followed by 10% neutral buffered formalin. The fixed brains and hearts were then removed, sectioned, and stained with hemotoxylin and eosin (H&E) to assess tissue damage and to verify the location of the tip of microdialysis guide cannula. Brain and heart pathology was analyzed as previously published (McDonough et al., 1995). Animal tissues were evaluated by a board-certified veterinary pathologist who was unaware of the experimental history of a given subject.

Data analysis

For RBC AChE data and numerical data in the FOB, a one-way analysis of variance (ANOVA) was used to determine whether significant differences existed. For body weight change data, gait angle data, and foot splay data, a two-way (treatment × day) repeated measures ANOVA was used. Post hoc Tukey tests were then further used to identify significant effects. For the results of the categorically scored (yes no) parts of the FOB, Kruskal-Wallis ANOVA on ranks (Hollander and Wolfe, 1973) was used to detect whether there were significant differences between baseline group scores. A Wilcoxon signed-rank test was then used to detect statistical differences between the same individual animals before and after sarin treatment. A difference of P < 0.05 was considered significant. The EEG power spectra data were graphed as a function of day of injections with time period reflected on the x-axis. Each bar reflects the mean for that particular day and time period taken over 120-s time snippet within the time period. A two-factor ANOVA (group: saline vs. sarin exposure; time: 15, 30, 45, 60, 75, 90, 105, and 120 min after atropine dosing), with repeated measures on the time factor, was used for analysis of the ACh microdialysis data.

Results

Pilot study

None of the lower doses of sarin (0.3, 0.4, and 0.5 × LD50) elicited epileptiform seizure activity during periods of EEG recordings in any of the animals in either the pilot study or main experiment. However, there were noticeable signs (hyperexcitability, muscle tremors, piloerection, chewing) of nerve agent intoxication in all animals receiving the 0.6 × LD50 sarin dose (n = 4) by the 2nd day of injections. The 0.6 × LD50 sarin dose caused seizures in 2 of the 4 guinea pigs by the 4th day of injections and death in 3 of 4 guinea pigs before the final day of injections. Thus, the 0.6 × LD50 dose of sarin did not meet the predetermined criterion and was disqualified for use in further studies. The 0.4 and 0.5 × LD50 sarin doses were chosen for full experimentation because they were the highest possible doses that did not elicit cortical EEG seizures nor produce death when given over the 2 weeks of daily injections. The weight gain and
RBC AChE data from the 4 animals in each pilot study treatment group (saline, 0.4 × LD₅₀, and 0.5 × LD₅₀) were added to the data obtained from the animals in the full experiment. This was done to increase the overall number of animals available for statistical analysis of weight gain and RBC AChE data only. In the full experiment, there were 24 animals that received saline or 0.4 × LD₅₀ sarin (final total n = 28 for saline and n = 28 for 0.4 × LD₅₀) and 9 animals that received 0.5 × LD₅₀ sarin in the full experiment (final total n = 13). The reason for the lower number of guinea pigs receiving 0.5 × LD₅₀ sarin is explained below.

**Neurotoxicity**

While all 4 guinea pigs receiving 0.5 × LD₅₀ sarin in the pilot study survived without seizures for the 10 injections, this was not the case in the full experiment, where 2 of the 9 guinea pigs receiving 0.5 × LD₅₀ sarin died before the 2 weeks of injections were completed. These 2 animals never showed signs of EEG epileptiform seizures. Therefore, while the 0.5 × LD₅₀ sarin dose given in the pilot study met predetermined criteria, the same dose in the full experiment did not. For this reason, we terminated further use of the 0.5 × LD₅₀ dose of sarin, and the total number of animals given this dose was 13 (4 from the pilot study + 9 from the full experiment).

**Weight changes**

The guinea pigs showed dose–response changes in body weight over the 2 weeks of injections (Fig. 1). The overall average weight gains (calculated as the animal's weight on the 10th day of injections minus the animal's weight prior to the first injection) for the animals receiving saline, 0.4 and 0.5 × LD₅₀ sarin were 56.89 ± 2.36, 51.6 ± 2.81, and 30.09 ± 5.25 (mean ± SEM) g, respectively. The two-way ANOVA, with repeated measures on days, showed significant main effects for treatment ($F_{(2,64)} = 8.18$, $P < 0.001$), days ($F_{(8,512)} = 263.39$, $P < 0.001$), and the treatment × days interaction ($F_{(8,512)} = 8.81$, $P < 0.001$). Both the saline control and 0.4 × LD₅₀ sarin groups gained significantly greater amounts of weight than did the 0.5 × LD₅₀ sarin group throughout the 10-day exposure period. These weight differences first reached significance on day 5, and became even more notable over the next week, with the 0.5 × LD₅₀ sarin group gaining significantly less weight than either the saline controls or the 0.4 × LD₅₀ sarin group on injection days 6–10. There was no significant difference between the weight gains of the saline controls and the 0.4 × LD₅₀ sarin group on any day during the dosing period.

**RBC AChE changes**

As shown in Fig. 2, by the 2nd day of sarin injections, RBC AChE in the guinea pigs receiving 0.5 × LD₅₀ sarin had dropped to 14% of baseline values, which was significantly ($P < 0.001$) lower than the 35% of baseline RBC AChE levels in animals receiving 0.4 × LD₅₀ sarin. However, by the 10th day of sarin injections, RBC AChE levels had dropped to near identical levels (11% vs. 12% of baseline values, respectively) in the 0.4 and 0.5 × LD₅₀ animals. The average 2-day weekend (Saturday–Sunday) RBC AChE recovery between the 2 weeks of sarin injections was 17% and 20%, respectively, for the 0.4 and 0.5 × LD₅₀ sarin groups. Even 21 days after termination of the injections, the RBC AChE levels of the

---

**Fig. 1.** Weight change vs. day of sarin injection. The animals were weighed prior to the first sarin injection and then before each subsequent day's injection. Data are graphed as the change between the initial weight and the weight prior to each day's sarin injections. Values are expressed as means ± SEM. $n = 28$ for saline group, $n = 28$ for 0.4 × LD₅₀ sarin group, $n = 11$ for 0.5 × LD₅₀ sarin group. (There were 13 guinea pigs in total, but 2 guinea pigs died before the 8th day of injections and thus were not able to be included in statistical analysis using a two-way repeated measures ANOVA.) There is a dose–response change in weight in relation to the dose of sarin given. The animals receiving the 0.5 × LD₅₀ dose of sarin showed significantly less overall weight gain ($P < 0.005$) than the animals receiving either saline or 0.4 × LD₅₀ sarin.
Fig. 2. RBC AChE levels vs. day of sarin injection. Blood was taken via toe-nail clip at different times during the sarin injections, and RBC AChE levels were determined by standard methods. To reduce animal discomfort, blood was not drawn from every animal on every occasion except for baseline values. Values are expressed as means ± SEM with a minimum n = 7 RBC samples (each run in triplicate) for each data point. By the 2nd day of sarin injections, RBC AChE in the animals receiving 0.5 × LD50 sarin injections dropped to significantly (P < 0.001) lower levels than in the 0.4 × LD50 sarin animals. However, by the 10th day of sarin injections, RBC AChE levels were nearly identical (11% vs. 12% of baseline values) in the 0.4 × LD50 and 0.5 × LD50 sarin groups. At 21 days recovery, RBC AChE levels in the animals receiving 0.4 × LD50 and 0.5 × LD50 sarin had returned to 68% and 67% of baseline values, respectively. *P < 0.01 vs. 0.4 × LD50 sarin group.

Neurobehavioral (FOB) testing

Both the guinea pigs receiving saline and those receiving 0.4 × LD50 sarin became significantly (P < 0.05) easier to remove from their cages when comparing FOB scores after the 10th injection with those scores obtained at baseline (Table 1). The average “cage removal” score (mean ± SEM on a scale from 1 to 3) went from 1.50 ± 0.13 to 1.04 ± 0.04 and from 1.83 ± 0.2 to 1.0 ± 0.0 for the saline and 0.4 × LD50 sarin animals, respectively. The guinea pigs receiving saline and 0.4 × LD50 sarin also became significantly (P < 0.05) easier to handle over the same time period. The average “handling” score (mean ± SEM on a scale from 1 to 4) went from 2.54 ± 0.15 to 2.04 ± 0.04 for the animals receiving saline and from 2.50 ± 0.12 to 1.96 ± 0.04 for the animals receiving 0.4 × LD50 sarin. The guinea pigs receiving saline also developed significantly (P < 0.05) decreased approach (2.04 ± 0.19 to 1.29 ± 0.14 on a scale from 1 to 6) and touch (2.21 ± 0.2 to 1.46 ± 0.2 on a scale from 1 to 6) responses over the same period. In contrast, the animals receiving 0.4 × LD50 sarin failed to show any significant decreases in their approach and touch response scores when comparing their baselines with their scores after the 10th sarin injection. The 0.5 × LD50 sarin animals failed to show significant changes in removal from cage, touch response, and approach response, and they did not adjust to handling. No significant changes in FOB scoring were observed for any of the other measurements in any of the three groups (Table 1).

A two-way repeated measures ANOVA of gait angles revealed significant main effects for treatment group (F(2,52) = 16.05, P < 0.001) and days (F(7,364) = 2.04, P = 0.05); the treatment group × days interaction was not significant. These data are displayed in Fig. 3. The 0.5 × LD50 sarin group had significantly greater gait angles than did the saline controls or the 0.4 × LD50 sarin group; there was no difference between the gait angles of the animals receiving saline and those receiving 0.4 × LD50 sarin. In general, the guinea pigs injected with 0.5 × LD50 sarin tended to keep their hindfeet parallel to each other and hop rather than alternate steps as did the saline control and 0.4 × LD50 sarin guinea pigs. This is illustrated by measuring the angle between consecutive footprints (Fig. 4). Additionally, the drop reflex was impaired in 2/9 guinea pigs treated with 0.5 × LD50 sarin; this was never observed in the saline controls or animals receiving 0.4 × LD50 sarin. It was also observed that the animals receiving 0.5 × LD50 sarin showed obvious muscle tremors upon attempts to move. In contrast, muscle tremors were never observed in the animals receiving the 0.4 × LD50 dose of sarin. There were no differences between any of the groups in hindlimb foot splay or touch responses over any time (Fig. 5).

EEG spectral analysis

The total EEG power recorded during the baseline period of each day of exposure, as well as on the 6th day of recovery, was not different between the saline, 0.4 × LD50 sarin and 0.5 × LD50 sarin groups (Fig. 6A). For the most part, on any given day of injection or recovery, the total EEG power would generally increase, when compared with the baseline power, as the recording periods moved further.
from the same individual groups of animals during the same time period on the first day of injections. The total powers, during the P5 period, on the 6th day of recovery for the animals receiving saline, 0.4 and 0.5 × LD50 sarin were 8959.22, 6714.52, and 2965.58, respectively. These values amount to 167, 131, and 59% of the power values obtained from the same individual groups of animals during the same time period on the first day of injections. There were noticeable differences in total spectral EEG power for the saline, 0.4 × LD50 sarin and 0.5 × LD50 sarin groups. When total power was broken down into frequency bandwidths, the most prominent changes were in the delta (Fig. 6B) and theta (Fig. 6C) bands, with some changes in the alpha (Fig. 6D) and beta I (Fig. 6E) bands. Most notably, the delta and theta activity of 0.5 × LD50 sarin group did not display any increase over the daily recording period (P1–P5) on the 10th day of injections or the 6th day of recovery, while such an increase was quite prominent in the saline and 0.4 × LD50 sarin groups. There was a significant increase (P < 0.05) when compared to the same period on day 1, in high-frequency beta II activity (Fig. 6F) during the baseline period on day 10 and after 6 days of recovery in all treatment groups.

**Neurochemistry**

While choline levels were initially elevated in saline-treated animals in the microdialysis phase of the study relative to the sarin-treated animals, this difference never reached significance at any time (Fig. 7). The initial elevation and trend towards a reduction in choline from the start of fraction collection in the saline-treated animals could be attributed to a gradual decrease in remaining endogenous AChE activity in the brain due to the inclusion of neostigmine in the perfusion buffer. The neostigmine (a carbamate AChE inhibitor) prevents the breakdown of ACh into choline. In the sarin-treated animals, AChE activity was already inhibited because of the actions of the nerve agent. Therefore, there was a resulting decrease in choline formed as a byproduct of ACh breakdown.

**Baseline levels of ACh** (calculated as the average of the last 2 fractions before atropine sulfate injection) were slightly higher, although not significantly, in the sarin-treated animals than in saline-treated animals (data not shown). Analysis of the ACh data showed no significant group effect, nor group × time interaction. There was, however, a significant effect of time, with significant increases in ACh values at the 45-, 60-, 75-, and 90-min time points relative to the 15-min time point (Fig. 8). This demonstrates the stimulating effects of atropine on ACh output. In addition, simple main effect tests showed that the sarin-treated group contributed the most to this increase; there were no significant differences in ACh levels of the salinetreated group over the 8 time points, while for the sarin-treated group, ACh was significantly elevated above their 15 min levels at the 60- and 90-min samples (P < 0.05) and the 75-min sample elevation just missed the conventional level of significance (P < 0.07).
Fig. 3. Gait angle vs. day of sarin injection. This figure shows the changes in the guinea pig's angle of gait vs. the day of injections for saline and the different concentrations of sarin (0.4 × LD₅₀ and 0.5 × LD₅₀). The gait angle is measured as described in Materials and methods. Values are expressed as means ± SEM. n = 24 for saline group, n = 24 for 0.4 × LD₅₀ sarin group, n = 7 for 0.5 × LD₅₀ sarin group. (There were 9 guinea pigs in total, but 2 guinea pigs died before the 8th day of sarin injections and thus were not included in statistical analysis using a two-way repeated measures ANOVA.) A repeated measures ANOVA showed that overall (main effect) the 0.5 × LD₅₀ sarin group had significantly greater gait angle than the saline controls or the 0.4 × LD₅₀ sarin group, which did not differ from one another.

The average angle between hindlimb steps is exaggerated in the 0.5 × LD₅₀ sarin group because they tended to hop rather than walk.

ACh release was measured in the presence of neostigmine (2 μM) to increase the detectability of baseline ACh levels. Part of the measured increase in ACh levels after atropine in both treatment groups (Fig. 8) may be due to the neostigmine-

![Hindlimb Gait](image)

Fig. 4. Hindlimb gait. These figures are representative samples of guinea pig hindlimb gaits. The footprints on the left are from a saline control guinea pig after the 6th day of injections. The footprints on the right are from a guinea pig that had received 10 injections of 0.5 × LD₅₀ sarin. The animals were required to walk in a relatively straight line for a minimum of 3 successive steps. Lines were drawn from a similar point on each foot, and the angle that is formed between the furthest foot back, the opposite foot, and the next step of the first foot was measured with a protractor.

elevated basal ACh dialysate levels (de Boer et al., 1990; Kawashima et al., 1991). As a result, atropine-stimulated ACh levels could potentially be higher for both treatment groups if neostigmine were not used. However, the underlying ACh release pattern should not be affected because neostigmine-stimulated release would again be normalized to basal levels for each respective group.

Pathology

No evidence of brain or heart pathology was found in any guinea pig that survived all 10 sarin (0.3, 0.4 or 0.5 × LD₅₀) injections. Animals that died during experimentation were not submitted for postmortem examination, because they died overnight and were not found until the next morning. It was verified in each case that the tip of the brain microdialysis probe was within the caudate nucleus.

Discussion

One of the objectives of the current set of experiments was to establish a dose of sarin to be utilized in a model for further study of the effects of low-dose repeated exposure to sarin in the guinea pig model. A primary requirement of the model was to determine a dose of sarin that could be given over a 2-week period without causing identifiable cholinergic signs of toxicity. Although no guinea pigs in the 0.5 × LD₅₀ sarin group showed signs of epileptiform seizures, 2 of 13 (15%) animals died before all 10 sarin injections were given. This dose also caused a rapid decrease in RBC AChE levels to approximately 10% of baseline values by the 2nd day of sarin injections. Additionally, there were noticeable signs of sarin intoxication (chewing, hyperactivity, muscle tremor),
Hindlimb Foot Splay

Fig. 5. Hindlimb foot splay vs. day of sarin injection. This figure shows the hindlimb foot splay (in cm) vs. the day of sarin injections for the saline, 0.4 and 0.5 x LD50 sarin groups. The animal's feet were painted with tempura paint, and the animal was dropped from approximately 30 cm onto a piece of paper. The distance between the footpads under the middle toe on each foot was measured. Each drop was performed in duplicate and averaged (n = 24 for saline group, n = 24 for 0.4 x LD50 sarin group, and n = 7 for 0.5 x LD50 sarin group). The values are expressed as means ± SEM. There are no statistical differences between the hindlimb splay of the guinea pigs injected with saline vs. those injected with either 0.4 or 0.5 x LD50 sarin.

alterations in angle of gait (Fig. 3), and impaired drop reflexes in some of the guinea pigs receiving 0.5 x LD50 sarin. Youssef and Santi (1997) showed that multiple low-dose injections of either acrylamide or methanol, both known neurotoxicants, resulted in changes in the angle of gait similar to those observed in the study presented here. Moser (1995) used similar neurobehavioral screening batteries after a single acute dose of 7 different AChE inhibitors and concluded that altered gait could be considered a "cardinal sign of toxicity for cholinesterase inhibitors." The gait problems identified in the animals receiving 0.5 x LD50 sarin were accompanied by significant reductions in body weight gains over the same periods. Since our experiments did not include a group solely to look at the effect of weight loss on gait, we cannot completely rule out its potential contribution to this effect. In contrast to 0.5 x LD50 sarin group, the animals receiving 0.4 x LD50 sarin showed no signs of toxicity. This finding confirmed the report of Atchison et al. (2004) that in guinea pigs dosed once daily for 2 weeks with 0.4 x LD50 sarin had no signs of toxicity. The fact that we found no evidence of brain pathology in any of the animals that received all 10 sarin (0.3, 0.4, or 0.5 x LD50) injections (cumulative doses of 3, 4, and 5 x LD50, respectively) indirectly supports prior studies showing that nerve agent-induced brain pathology is primarily seizure-mediated (McDonough et al., 1989, 1995; Shih et al., 2003) and not due to the total dose of nerve agent.

By the 2nd day of sarin injections, RBC AChE levels in animals receiving the 0.5 x LD50 dose had dropped significantly lower (14% of baseline values) than the RBC AChE levels in animals receiving 0.4 x LD50 sarin (Fig. 2). The parallels between the onset of signs following the second 0.5 x LD50 sarin injection and the rapid reduction of the RBC AChE levels to approximately 14% of control values after the 2nd injection are consistent with the results of Grob and his associates. They found that the onset of signs upon human exposure to DFP (Grob et al., 1947) or sarin (Grob and Harvey, 1958) was correlated with rapid decreases of RBC AChE levels to 30 and 22% of baseline values, respectively. However, when the OPs were administered at lower doses over several days, there was no correlation between the onset of signs and RBC AChE levels (Grob et al., 1947). This is consistent with our studies in which RBC AChE in the animals receiving 0.4 x LD50 sarin had dropped to 11% of baseline values by the 10th day of sarin injections, yet showed no obvious signs of nerve agent intoxication despite RBC AChE levels identical to those of 0.5 x LD50 sarin group. It is commonly accepted that the only way that RBC AChE can be replaced once it is irreversibly inhibited by nerve agents is by de novo synthesis (Harris et al., 1971) of new RBCs, which is thought to occur at the rate of 1-2% per day (Grob and Harvey, 1958). Therefore, we must rule out the possibility that daily replenishment alone of RBC AChE is accounting for the failure of RBC AChE levels in our animals to fall below 10% of baseline values. The failure of RBC AChE to fall below 10% of baseline levels is most likely a combination of de novo RBC AChE synthesis (Grob and Harvey, 1958; Harris et al., 1971) and an increasing rate of spontaneous reactivation of RBC AChE associated with repeated exposures to nerve agents (Lanks et al., 1977).

The increase in EEG spectral power that the saline animals showed from the time of injection (BL) to 30-36 min after injection (P5) was more pronounced at the lower frequency bandwidths (delta, theta, and, to a lesser extent, alpha). It is most likely that the increase in EEG power from the time of injection
to 36 min after injections was a result of the animals falling asleep. Unlike the animals that received saline, animals that received 0.5 × LD₅₀ sarin for 10 exposures showed no increases in power over the time periods during the later sarin exposures, while the changes in the 0.4 × LD₅₀ sarin-treated group were intermediate between that of the saline and 0.5 × LD₅₀ sarin group. The differences in total and lower frequency band powers between the 0.5 × LD₅₀ sarin animals and the saline animals persisted into the 6th day of recovery. While our findings of significant changes in high frequency beta II spectra support purported changes in beta II powers reported by Burchfiel et al. (1976), we also saw similar changes in animals
Choline Levels

Fig. 7. Striatal choline levels in sarin-treated vs. saline-treated guinea pigs. Saline- (○) and 0.4 × LD₅₀ sarin- (*) treated guinea pigs were allowed to recover for 10–12 days before undergoing microdialysis collection from the caudate nucleus. The amount (pmol) of choline (mean ± SEM), contained in one 15-min fraction (3 μl/min) of dialysate, is graphed against the time of the fraction in relation to the injection of atropine sulfate (5 mg/kg, i.p.). While there is a measurable difference between the mean (±SEM) values of choline in the sarin-treated animals as compared with the saline-treated animals, the difference fails to reach significance at any time. The trend towards a reduction in choline from the start of fraction collection in the saline-treated animals can be attributed to a gradual decrease in remaining endogenous AChE activity in the brain due to the inclusion of neostigmine in the perfusion buffer. The neostigmine prevents the breakdown of ACh into choline. In the sarin-treated animals, AChE activity is already inhibited because of the actions of the nerve agent. Therefore, there is a resulting decrease in choline formed as a byproduct of ACh breakdown.

that had received saline. Overall, these data suggest that repeated low-dose sarin exposures may disrupt normal cortical EEG sleeping patterns. While these disruptions were able to return to relative normalcy 6 days after the last injection in the animals receiving 0.4 × LD₅₀ sarin, this change persisted in the 0.5 × LD₅₀ sarin group for at least 6 days after the last injection. Changes in sleep have been prominently mentioned in clinical reports of individuals exposed to high doses of sarin or soman (Sidell, 1974; Nozaki et al., 1995) as well as less toxic levels of exposure (Metcalf and Holmes, 1969).

ACh increase after atropine

Fig. 8. ACh in sarin-treated vs. saline-treated guinea pigs. The increase in measurable ACh (mean ± SEM) as compared with baseline values before atropine sulfate injection has been graphed for the 0.4 × LD₅₀ sarin- (dark bars) and saline- (light bars) treated guinea pigs vs. time after atropine sulfate (5 mg/kg, i.p.) injection. The data have been normalized to take into account the differences between baseline ACh values between the 2 groups. Therefore, a value of 1 on the y-axis is equal to a value of ACh (pmol) that is 100% of the baseline measurements prior to atropine injection. Analysis of the ACh data showed no significant group effect or group × time interaction. There was a significant increase in ACh levels in both groups as a function of time; ACh levels at 45-, 60-, 75-, and 90-min were elevated relative to the 15-min sample. Simple main effects showed that the sarin-treated group contributed most to this effect; the samples of the 60- and 90-min time points being significantly elevated compared to the 15-min sample. Only at the 15-min time point was there a significant increase in ACh levels of the sarin-treated group relative to the saline controls.
Repeated sarin exposure had no effect on many of the FOB measures (Table 1). However, the 0.4 and 0.5 × LD₅₀ sarin-treated animals showed decreased ability to habituate to certain aspects of the neurobehavioral testing, unlike their saline control counterparts. The guinea pigs used for the experiments were handled very minimally prior to the first day of injections. Thus, the significant decreases observed in removal from cage and handling were due to the guinea pigs becoming acclimated to being handled by the technician scoring the FOB. It is also most likely that the saline-treated guinea pigs became less reactive to an approaching pencil (approach response) and to a touch on the rump (touch response) because of this habituation. In contrast, the animals receiving 0.4 or 0.5 × LD₅₀ sarin failed to accclimate to some aspects of the FOB testing (approach and touch responses for the 0.4 × LD₅₀ sarin dose, and handling, cage removal, and approach and touch responses for the 0.5 × LD₅₀ sarin dose). It is worthy of noting that the FOB scores after the 10th day of sarin injections, for both the 0.4 and 0.5 × LD₅₀ sarin doses, were not “worse” than they were at baseline measurements. In short, the animals receiving sarin did not habituate to certain subtest of the FOB compared to the guinea pigs receiving saline. It was interesting to note that, in our previous study (Shih et al., 1990) in which rats were injected (s.c.) with 0.4 × LD₅₀ of soman 3 times (M, W, F) a week for up to 6 weeks, the animals became hyper-reactive to normal handling procedures and demonstrated exaggerated startle responses to air puffs.

Thus, guinea pigs receiving 0.4 × LD₅₀ sarin for 2 weeks of daily repeated exposure (Mondays–Fridays) were virtually indistinguishable in gross behavior and body weight changes from those that received saline over the same time period. In spite of these observations, animals that received 0.4 × LD₅₀ sarin showed a decrease of their RBC AChE to approximately 10% of baseline levels by day 10. The 0.4 × LD₅₀ sarin dose inhibited RBC AChE to levels equivalent of the 0.5 × LD₅₀ group without producing the overt signs of acute sarin exposure (gait impairment, tremor) observed in this group. However, the FOB revealed that both groups showed very subtle neurobehavioral changes. The understanding of whether these subtle neurobehavioral changes can last for extended postexposure periods and whether these neurobehavioral changes can progress in severity may be important for investigating the potential health hazards of low level exposure (based on RBC AChE recovery data shown in Fig. 2). However, in our studies, there was no statistical difference between the levels of striatal ACh from animals that had received 0.4 × LD₅₀ sarin injections vs. those that had received saline injections. Two possible explanations for this come to mind: (1) the 10–12 days between the last sarin injection and the taking of the dialysate samples was sufficient for striatal AChE levels to return to normal, or (2) the prolonged inhibition of extracellular AChE led to a prolonged increase in extracellular ACh. The prolonged availability of ACh in the synaptic cleft results in feedback inhibition on muscarinic, presynaptic autoreceptors to decrease further ACh release (Russell et al., 1985). Should the latter of these hypotheses be correct then we would expect that a sudden release of the feedback inhibition would result in a rapid release of ACh into the cleft. Indeed, this may be the case. Atropine works as a competitive ACh antagonist at both pre- and postsynaptic receptors and, therefore, is able to terminate presynaptically the controls of feedback inhibition. Within 15 min after the atropine injection, there was a substantial (approximately 1.5 times) increase in ACh in the striatal dialysate of the sarin-treated group relative to the increase in ACh dialysate from saline controls. This greater ACh increase in the sarin exposed group may be due to the known down-regulation of muscarinic receptors in response to chronic OP exposure (Churchill et al., 1984) and the resultant supersensitivity to cholinergic blocking agents such as atropine (Modrow and McDonough, 1986). The observable trend of a reduction in measurable choline in the animals receiving sarin compared to those receiving saline is most likely due to the decrease in AChE in the cleft of animals treated with sarin. This would lead to a decrease in ACh breakdown and, therefore, a reduction in measurable choline. Indeed the initial high choline measurements, evident in the animals that had received saline, begin to decrease to approximately the same choline levels seen in the animals that had received sarin, as more neostigmine was infused with the dialysate buffer. Neostigmine was thus acting in the same manner as the nerve agent; decreasing the breakdown of ACh results in a decrease of its breakdown products, the major component being choline. These trends of neurochemical results at 10–12 days after 2 weeks of chronic 0.4 × LD₅₀ sarin injections lead us to suggest that the normal brain NT and receptor homoeostasis are still disrupted at this time, at least in the striatum, but most probably throughout the whole cholinergic system in the brain. It is, therefore, speculated that these prolonged sarin-induced alterations in brain chemistry may be the pharmacological basis for the neurobehavioral and EEG changes observed in the present study.

Acknowledgments

This research was supported by a National Research Council Research Associateship to Dr. S. W. Hulet from January 2000 to September 2001. The authors express their great appreciation to Mrs. T. Rowland and Ms. L. Rechen for serving as scorers on the functional observational battery testing and to Dr. S. M. Duniho, D.V.M. for pathological evaluation. The authors would also like to thank Mr. J. Barnwell, Ms. M. Zilka, Mr. J. McMonagle, Mr. A. Benjamin, and Mrs. C. Clark for their excellent technical assistance.
## Appendix A

### FUNCTIONAL OBSERVATIONAL BATTERY SCORE SHEET

<table>
<thead>
<tr>
<th>Date</th>
<th>Guinea pig #</th>
<th>Weight</th>
<th>Scoring code</th>
<th>Time started</th>
<th>Scorer</th>
</tr>
</thead>
</table>

#### Home Cage Assessment

<table>
<thead>
<tr>
<th></th>
<th>yes</th>
<th>no</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agitated</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chewing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Facial Dyssmphia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tremors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vocalizations</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Animal handling

Ease of removal from cage: (R) (choose one)

1. Easy; little or no vocalization, without resistance
2. Moderately easy; animal jumpy, initial movement followed by settling, with or without vocalizations
3. Difficult; runs around cage, is hard to grab, with and without vocalizations

Ease of Handling Guinea Pig in hand: (R) (choose one)

1. Easy, but lethargic
2. Easy, but alert, limbs may be pulled against body
3. Moderately easy; vocalizations, little or no squirming
4. Difficult, squirming, twisting, attempting to bite, with or without vocalizations

Lacrimation: (R) Salivation: (R) Fur Appearance: (R) (choose one for each)

<table>
<thead>
<tr>
<th></th>
<th>none</th>
<th>slight</th>
<th>severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>1.</td>
<td>2.</td>
<td>3.</td>
</tr>
<tr>
<td>2.</td>
<td>none</td>
<td>slight</td>
<td>severe</td>
</tr>
</tbody>
</table>

#### Open Field Checklist (2 minutes)

Latency to the first movement (sec)  
Total # of grooming episodes (C)  

Arousal: (R) (choose one)

1. Very low (little or absent)
2. Low (some head or body movement)
3. Somewhat low (some exploratory movements with period of immobility)
4. Normal (alert, exploratory movements)
5. Somewhat high (slight excitement, sudden darting or freezing)
6. Very high (hyper-alert, excited, sudden bouts of running or body movements)

Gait description: (D) (choose one)

1. No movement
2. Normal
3. Impairment
   a. Uncoordinated movement (ataxia)
   b. Walking on toes
   c. Splayed hind limbs
   d. Exaggerated hind limb flexion
   e. Staggered gait
   f. Dragging hind limbs
   g. Unable to walk

Total # of fecal boluses (C)  
Total # of urine spots (C)
Reflexes

Click Response: (R) (choose one)
1. no reaction
2. slight reaction, ear flick or some evidence that sound was heard
3. more energetic response than (2); may include vocalization
4. jumps, seems startled
5. freezes, actual muscle contraction
6. bizarre reaction: bites, attacks

Approach response: (R) (choose one)
1. no reaction
2. slow approach, sniffing or turning away
3. more energetic response than (2), possible vocalizations
4. jumps, makes efforts to avoid object
5. freezes, actual muscle contraction
6. bizarre reaction: bites, attacks

Touch Response: (R) (choose one)
1. no reaction
2. slowly turns, walks away
3. more energetic response than (2), possible vocalizations
4. jumps, makes efforts to avoid object
5. freezes, actual muscle contraction
6. bizarre reaction: bites, attacks

Gait scoring: (C) (I trial)
<table>
<thead>
<tr>
<th>Stride length (cm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stride width (cm)</td>
</tr>
<tr>
<td>Angle</td>
</tr>
</tbody>
</table>

Foot Splay Measurements (2 trials)

| trial 1 (cm) | trial 2 (cm) |

Righting Reflex: (R)
1. normal (immediately rights itself)
2. slightly impaired (>1 sec)
3. impaired (>2 sec)
4. totally impaired (remains on back)

Drop Reflex: (R)
1. normal
2. slightly uncoordinated
3. lands on side
4. lands on back

COMMENTS:

References


